Navigation Links
MicuRx Pharmaceuticals Announces Issuance Of U.S. Patent For Its Next-Generation Antibacterial Agent
Date:5/23/2012

HAYWARD, Calif., and SHANGHAI, May 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens.

"This patent is expected to be the first of a series to issue," said Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx. "With a scarcity of new antibiotics in development and ever-increasing bacterial resistance, we believe that MRX-I, with its high antimicrobial potency and enhanced safety profile, could offer a valuable option for treatment of infections caused by multi-drug resistant Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE)." 

"We are pleased that the USPTO has affirmed MicuRx's intellectual property rights by granting this key patent for our first antibiotic candidate," added Mike Gordeev, Ph.D, chief scientific officer and executive vice president of MicuRx.

Multi-Drug Resistance: A Growing Global Public Health Crisis

Modern antibiotics have substantially reduced the threat posed by infectious diseases and contributed to a dramatic drop in mortality rates over the past 40 years. However, pathogenic bacteria resistant to current therapies have evolved over the years and become ubiquitous. The World Health Organization, Centers for Disease Control and the Infectious Disease Society of America have identified multi-drug resistant bacteria as a major public health threat today and into the future. According to the Center for Disease Control and Prevention, about 70 percent of U.S. hospital infections are resistant to at least one of commonly used antibiotics. In certain regions, the incidence of drug-resistant MRSA in hospital-acquired infections is recognized as a major health threat. MicuRx's agents directly address the escalating problem of multi-drug resistant bacteria, with a potential for deployment in both hospital and community-based settings. 

About MicuRx Pharmaceuticals, Inc.

MicuRx is discovering and developing novel antibiotics to combat infections due to resistant bacteria. Positioned to capture the benefits of United States research and development expertise together with the high quality, low cost discovery, preclinical and development infrastructure in China, the company has built a pipeline of discovery and development programs for the treatment of Gram-positive bacteria, Gram-negative bacteria and fungal infections. The company has research and development facilities outside San Francisco, CA in the United States and in Shanghai, China.  MicuRx has raised $12 million in Series A venture funds from Morningside Group (http://www.morningside.com/) and Devon Park Bioventures (http://www.dpbioventures.com/).


'/>"/>
SOURCE MicuRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MicuRx Pharmaceuticals Files Investigational New Drug Application for MRX-I
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... DC (PRWEB) , ... May 26, 2016 , ... There ... National Hot Dog and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight ... dogs, 63 percent say grilling is their favorite way to cook a hot dog, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... ... discovery of thousands of defective respirators, according to court documents and SEC filings. ... of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los ...
(Date:5/26/2016)... ... May 26, 2016 , ... Georgia State University ... specialty academic programs. , Answering to the increasing demand for curricular specializations, the ... law, and environmental and land use law. ,  , “The demand for lawyers ...
(Date:5/26/2016)... ... ... On Memorial Day, Hope For Heroes and USA Medical Card will ... country. The nonprofit Hope For Heroes partnered with the leading provider of free ... military veterans, as well as police, firemen, and EMS professionals across the country, and ...
Breaking Medicine News(10 mins):